Larvol Clinic's blog

Metastatic Breast Cancer by Circulating Tumor DNA

Larvol Clinic's photo
Larvol Clinic
·

1 min read

RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.

PURPOSE: This clinical trial is looking at the CYP3A5 gene to see if having the gene may be a risk factor for kidney damage in young patients with cancer treated with ifosfamide.

OBJECTIVES:

Primary

  • To determine the CYP3A5 genotype in young patients with cancer who have received ifosfamide.

  • To document renal function and nephrotoxicity on one occasion between 1 month and 5 years after completion of ifosfamide treatment.

  • To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity.

Secondary

  • To compare the measured glomerular filtration rate (GFR) (using a radioisotope clearance method) with that calculated using the Cole (weight and creatinine) model.
CancerindiaGoogle